This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Valmori, D. Articles by Romero, P. Search for Related Content PubMed Articles by Valmori, D. Articles by Romero, P.

Analysis of MAGE-3-specific Cytolytic T Lymphocytes in Human Leukocyte Antigen-A2 Melanoma Patients

Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Division of Clinical Onco-Immunology [D.V., D.L., G.W., D.R., J-C. C., P.R.] and Pluridisciplinary Center of Oncology [D. L.], CHUV, 1011 Lausanne, Switzerland

The MAGE-3 gene is a member of a multigene family that is selectively expressed by subsets of different human tumor types, including malignant melanoma, but not by normal tissues except for testis and placenta. A cytolytic T lymphocyte (CTL)-defined MAGE-3 antigen, corresponding to the MAGE-3 peptide 271–279 associated with the human leukocyte antigen (HLA)-A2 molecule, has been recently identified using T lymphocytes from a normal individual stimulated in vitro with peptide-pulsed autologous antigen-presenting cells. Because MAGE-3 is expressed in 76% of metastatic melanomas, the HLA-A2-restricted MAGE-3 antigen should be expressed by approximately 37% of Caucasians bearing a metastatic melanoma tumor, thus representing an attractive candidate for the elicitation of specific CTL immune responses in vivo. In this study, we determined the proportion of HLA-A2⁺ melanoma patients displaying detectable MAGE-3 peptide 271–279-specific CTL precursors in peripheral blood. Peptide-specific CTL populations were obtained from at least 4 of 11 HLA-A2⁺ patients. Peptide-specific CTL lines derived from these populations readily lysed HLA-A2-positive target cells that were pulsed with MAGE-3 peptide 271–279 at nanomolar concentrations yet were unable to recognize (as assessed by cytolysis and cytokine production) MAGE-3-expressing autologous or allogeneic HLA-A2-positive melanoma lines. Similarly, the CTL lines failed to recognize MAGE-3-negative HLA-A2-positive tumor lines after transfection with the MAGE-3 gene, although they were able to recognize COS-7 cells transfected with MAGE-3. In contrast, HLA-A1-positive melanoma lines transfected with MAGE-3 were efficiently recognized by CTL lines directed against the MAGE-3 peptide 168–176, a known HLA-A1-restricted CTL epitope. These results suggest that the expression level of the MAGE-3 peptide 271–279, unlike that of MAGE-3 peptide 168–176, in melanomas may be too low to allow efficient recognition by specific CTLs. Thus, it appears that despite the presence of CTL precursors against MAGE-3 peptide 271–279 in some HLA-A2⁺ melanoma patients, the usefulness of this peptide for specific immunotherapy of melanoma may be limited.

¹ To whom requests for reprints should be addressed, at the Division d'Onco-Immunologie Clinique, Ludwig Institute, CHUV-BH19-602, 1011 Lausanne, Switzerland.

Received 9/10/96. Accepted 12/19/96.

This article has been cited by other articles:

				R. Sartorius, P. Pisu, L. D'Apice, L. Pizzella, C. Romano, G. Cortese, A. Giorgini, A. Santoni, F. Velotti, and P. De Berardinis The Use of Filamentous Bacteriophage fd to Deliver MAGE-A10 or MAGE-A3 HLA-A2-Restricted Peptides and to Induce Strong Antitumor CTL Responses J. Immunol., March 15, 2008; 180(6): 3719 - 3728. [Abstract] [Full Text] [PDF]

				S. Yang and F. G. Haluska Treatment of Melanoma with 5-Fluorouracil or Dacarbazine In Vitro Sensitizes Cells to Antigen-Specific CTL Lysis through Perforin/Granzyme- and Fas-Mediated Pathways J. Immunol., April 1, 2004; 172(7): 4599 - 4608. [Abstract] [Full Text] [PDF]

				D. Atanackovic, N. K. Altorki, E. Stockert, B. Williamson, A. A. Jungbluth, E. Ritter, D. Santiago, C. A. Ferrara, M. Matsuo, A. Selvakumar, et al. Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients J. Immunol., March 1, 2004; 172(5): 3289 - 3296. [Abstract] [Full Text] [PDF]

				S. Yang, G. P. Linette, S. Longerich, and F. G. Haluska Antimelanoma Activity of CTL Generated from Peripheral Blood Mononuclear Cells After Stimulation with Autologous Dendritic Cells Pulsed with Melanoma gp100 Peptide G209-2M Is Correlated to TCR Avidity J. Immunol., July 1, 2002; 169(1): 531 - 539. [Abstract] [Full Text] [PDF]

				R. Konopitzky, U. Konig, R. G. Meyer, W. Sommergruber, T. Wolfel, and T. Schweighoffer Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the Novel Overexpressed Tumor Antigen Calcium-Activated Chloride Channel 2 J. Immunol., July 1, 2002; 169(1): 540 - 547. [Abstract] [Full Text] [PDF]

				M. Ayyoub, S. Stevanovic, U. Sahin, P. Guillaume, C. Servis, D. Rimoldi, D. Valmori, P. Romero, J.-C. Cerottini, H.-G. Rammensee, et al. Proteasome-Assisted Identification of a SSX-2-Derived Epitope Recognized by Tumor-Reactive CTL Infiltrating Metastatic Melanoma J. Immunol., February 15, 2002; 168(4): 1717 - 1722. [Abstract] [Full Text] [PDF]

				I. C. Le Poole, A. I. Riker, M. E. Quevedo, L. S. Stennett, E. Wang, F. M. Marincola, W. M. Kast, J. K. Robinson, and B. J. Nickoloff Interferon-{gamma} Reduces Melanosomal Antigen Expression and Recognition of Melanoma Cells by Cytotoxic T Cells Am. J. Pathol., February 1, 2002; 160(2): 521 - 528. [Abstract] [Full Text] [PDF]

				M. Toungouz, M. Libin, F. Bulte, L. Faid, F. Lehmann, D. Duriau, M. Laporte, D. Gangji, C. Bruyns, M. Lambermont, et al. Transient expansion of peptide-specific lymphocytes producing IFN-{gamma} after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors J. Leukoc. Biol., June 1, 2001; 69(6): 937 - 943. [Abstract] [Full Text] [PDF]

				M. Larsson, D. Messmer, S. Somersan, J.-F. Fonteneau, S. M. Donahoe, M. Lee, P. R. Dunbar, V. Cerundolo, I. Julkunen, D. F. Nixon, et al. Requirement of Mature Dendritic Cells for Efficient Activation of Influenza A-Specific Memory CD8+ T Cells J. Immunol., August 1, 2000; 165(3): 1182 - 1190. [Abstract] [Full Text] [PDF]

				S. Yang, D. Kittlesen, C. L. Slingluff Jr., C. E. Vervaert, H. F. Seigler, and T. L. Darrow Dendritic Cells Infected with a Vaccinia Vector Carrying the Human gp100 Gene Simultaneously Present Multiple Specificities and Elicit High-Affinity T Cells Reactive to Multiple Epitopes and Restricted by HLA-A2 and -A3 J. Immunol., April 15, 2000; 164(8): 4204 - 4211. [Abstract] [Full Text] [PDF]

				F. Katsura, M. Eura, K. Chikamatsu, M. Oiso, E. Yumoto, and T. Ishikawa Analysis of Individual Specific Cytotoxic T Lymphocytes for Two MAGE-3-derived Epitopes Presented by HLA-A24 Jpn. J. Clin. Oncol., March 1, 2000; 30(3): 117 - 121. [Abstract] [Full Text] [PDF]

				D. Valmori, M. J. Pittet, C. Vonarbourg, D. Rimoldi, D. Lienard, D. Speiser, R. Dunbar, V. Cerundolo, J.-C. Cerottini, and P. Romero Analysis of the Cytolytic T Lymphocyte Response of Melanoma Patients to the Naturally HLA-A*0201-associated Tyrosinase Peptide 368-376 Cancer Res., August 1, 1999; 59(16): 4050 - 4055. [Abstract] [Full Text] [PDF]

				D. Valmori, U. Gileadi, C. Servis, P. R. Dunbar, J.-C. Cerottini, P. Romero, V. Cerundolo, and F. Levy Modulation of Proteasomal Activity Required for the Generation of a Cytotoxic T Lymphocyte-defined Peptide Derived from the Tumor Antigen MAGE-3 J. Exp. Med., March 15, 1999; 189(6): 895 - 906. [Abstract] [Full Text] [PDF]

				D. Valmori, J.-F. Fonteneau, C. M. Lizana, N. Gervois, D. Lienard, D. Rimoldi, V. Jongeneel, F. Jotereau, J.-C. Cerottini, and P. Romero Enhanced Generation of Specific Tumor-Reactive CTL In Vitro by Selected Melan-A/MART-1 Immunodominant Peptide Analogues J. Immunol., February 15, 1998; 160(4): 1750 - 1758. [Abstract] [Full Text] [PDF]

				I. Miconnet, C. Servis, J.-C. Cerottini, P. Romero, and F. Levy Amino Acid Identity and/or Position Determines the Proteasomal Cleavage of the HLA-A*0201-restricted Peptide Tumor Antigen MAGE-3271-279 J. Biol. Chem., August 25, 2000; 275(35): 26892 - 26897. [Abstract] [Full Text] [PDF]